ByonGuard™: Best-in-Class Masking Platform

Many tumor-associated antigens (TAAs) targeted by antibody therapies are also present in healthy tissue, causing on-target off-tumor toxicity, affecting treatment safety and limiting combination options. This fundamental challenge forces clinicians and patients to choose between efficacy and safety.

Our innovative ByonGuard™ platform, a best-in-class steric masking technology providing a universal solution to reduce off-tumor toxicity, aims to eliminate this trade-off. Unlike traditional masking approaches that demand custom peptide design for each target, ByonGuard™ offers a universal masking solution that can be applied broadly across multiple targets and antibody scaffolds, accelerating development timelines and expanding partnering flexibility.

ByonGuard™: Highly differentiated universal mask to reduce off-tumor toxicity

Novel Payloads

As ADCs move into earlier treatment lines and combination therapies, resistance to existing payloads is driving the need for novel payload classes. Byondis’s first-in-class antifolate payload platform addresses this challenge, leveraging a clinically validated mechanism of action not previously used in targeted therapy to overcome resistance to existing ADCs and offer new treatment options for non-responders.

Platforms

Our modular ADC platforms are generating potential first and best in class assets, including novel proprietary payloads, advanced masking technologies, and linker and drug conjugation strategies.

ByonGuard™: Best-in-Class Masking Platform

ByonGuard™: Highly differentiated universal mask to reduce off-tumor toxicity

Novel Payloads

Platforms

You are leaving Byondis.com